Investigation of Hypoxia-Inducible Factor 1-Alpha Levels and Its Change with High Flow Oxygen Therapy in COVID-19 Patients COVID-19 Hastalarında Hipoksi ile İndüklenebilir Faktör 1-Alfa Düzeyle-rinin ve Yüksek Akımlı Oksijen Tedavisi ile Değişiminin İncelenmesi
Genel Tip Dergisi, cilt.36, sa.2026, ss.1-6, 2026 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 36 Sayı: 2026
- Basım Tarihi: 2026
- Doi Numarası: 10.54005/geneltip.1452831
- Dergi Adı: Genel Tip Dergisi
- Derginin Tarandığı İndeksler: Scopus, Directory of Open Access Journals, TR DİZİN (ULAKBİM), Academic Search Ultimate (EBSCO)
- Sayfa Sayıları: ss.1-6
- Anahtar Kelimeler: COVID-19, hypoxia-inducible factor 1, oxygen inhalation therapy, ROC curve
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: In this study, we aimed to examine the change in Hypoxia-inducible factor 1-alpha (HIF-1α) levels and to determine the prognostic value of HIF-1α in COVID-19 patients receiving high-flow oxygen therapy. Materials and Methods: Our study was conducted on 30 patients who were followed up in the intensive care unit and 30 healthy volunteers. Enzyme-Linked Immunosorbent Assay method was used to measure HIF-1α concentrations. Correlations of HIF-1α levels with clinical, biochemical and radiographic data were analyzed. Results: When the HIF-1α levels of discharged and non-survivors COVID-19 patients were compared, it was found to be significantly higher in non-surviving patients (p = 0.016). Serum levels of HIF-1α in the COVID-19 group were significantly higher than in the control group (p<0.001). When the presence of subpleural and fibrotic bands on chest X-ray and HIF-1α levels were compared, a significant difference was found (p<0.001). Ac-cording to the Receiver Operating Characteristic (ROC) analysis results, the cut-off value for HIF-1α was 0.41, the sensitivity was 87%, the specificity was 89%, and the area under the ROC curve value was 0.95. Conclusion: We found that COVID-19 patients with severe disease have a significantly higher serum HIF-1α concentration. HIF-1α may be a potential therapeutic target for virus-induced inflammatory diseases and COVID-19.